Globally, lung cancer (LC) is the leading cause of cancer-related death.Nearly 85% of the malignant lung tumors occur due to non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). 1,2Although rapid advances have taken place in both lung cancer detection and treatment, and the 5-year survival rates are still inconclusive. 3 Nearly one-fourth of the patients with NSCLC are diagnosed with locally advanced stage (stage III) and have a poor prognosis. 4 For this condition, two treatment choices may be offered, induction chemotherapy followed by surgery or concurrent chemoradiation therapy. 5,6 Nevertheless, even with advanced surgical techniques and postoperative con-solidation chemotherapies, the local recurrence rates are 20-40%. 7 Many prognostic factors for lung cancer, such as tumor size, lymph node involvement, gender, age, weight loss, and smoking, may affect the course of the disease. 8 Recently several studies have reported that immunological parameters can affect the outcome. 9,10The systemic inflammatory response has an essential role in the development and progression of many solid tumors. 11Increased neutrophil count was found to be associated with poor prognosis, and lymphocyte count is an independent prognostic factor in solid cancers. 12Some methods to measure systemic inflammation were established, such as platelet to